EpilepsyGTX key facts
as of Oct 2026- Developer of gene therapies designed for neurological disorder treatment.
- EpilepsyGTX is valued at approximately $47.2M as of Oct 2026 (last reported valuation).
- It has raised $47.5M; the latest was Early Stage VC ($32.5M) in Dec 2025.
- Notable investors include British Business Bank, UK Research and Innovation, AlbionVC, Zcube, Health Technology Holding — 10 tracked in total.
- Status: Privately Held (backing).
EpilepsyGTX's last reported valuation, Dec 2025. Nothing priced has surfaced since.
- ·Watch EpilepsyGTX: the Monday email on marks, rounds and moves
EpilepsyGTX funding rounds
No funding rounds for EpilepsyGTX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
EpilepsyGTX valuation
EpilepsyGTX's last reported valuation was $47.2 million in Dec 2025. No priced round, secondary trade or fund mark has surfaced since.
EpilepsyGTX investors
10 investors are on record for EpilepsyGTX, including British Business Bank, UK Research and Innovation, AlbionVC and Zcube.
About EpilepsyGTX
Developer of gene therapies designed for neurological disorder treatment. The company's platform utilizes genetic engineering techniques to modify cells, delivering therapeutic genes to targeted areas within the brain, often involving viral vectors and specialized delivery systems, enabling researchers and clinicians to explore potential treatments for epilepsy.
- Sector
- Healthcare
- HQ
- Canterbury, United Kingdom
- Founded
- 2021
- Employees
- 2
- Website
- epilepsygtx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.